On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU PETER MANDELSON Member of the European Commission … Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/christinelagarde.html Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license To: Christine LAGARDE, Ministre déléguée au Commerce extérieur, France From: Manon Ress and James Love,… Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/cptech-mandelson10192005.html CPTech Letter to EC Director General of Trade Peter Mandelson 19th October 2005 Commissioner Mandelson EUROPEAN COMMISSION DG Trade 200 rue de la Loi B-1049 BRUSSELS Dear Commissioner Mandelson TRIPS Agreement and Avian Influenza We ask the… Continue Reading
Original page: http://www.cptech.org/ip/birdflu/ustr-birdflu.html 14 October 2005 Honorable Rob Portman United States Trade Representative 600 17th Street, N.W. Washington, DC 20508 Dear Ambassador Portman: We are writing to ask that the United States government address a mistake in trade policy that… Continue Reading
Original page: http://www.cptech.org/ip/wto/p6/cptech08302003.html CPTech Statement on WTO Deal on Exports of Medicines August 30, 2003 “Today’s decision on the implementation of paragraph 6 of the Doha Declaration on TRIPS and Public Health puts the WTO into unchartered waters. The WTO… Continue Reading